Palisade Bio Q2 net loss widens on higher R&D costs
PALI•Key figures
| Metric | Actual |
|---|---|
| Q2 loss per share | $0.05 |
| Q2 net loss | $10.57 mln |
| Q2 operating expenses | $12.2 mln |
| Q2 operating income | -$11.7 mln |
Expense drivers
- Increased R&D spending — Higher research and development expenses were driven by employee-related costs, stock-based compensation, and expanded PALI-2108 program activities.
- Milestone license revenue — License revenue was recognized from a milestone achievement in the co-development agreement with Newsoara.
Quarterly results
Palisade Bio's second-quarter net loss widened as research and development and administrative expenses increased.
The company said it recognized license revenue from a milestone achievement in its co-development agreement.
Clinical trial outlook and cash runway
The company expects to start its Phase 2 ASCENTRA-UC trial in the second half of 2026, with an efficacy readout in the second half of 2027.
An IND for the Phase 2 ASCENTRA-CD trial is expected in the second half of 2026, with trial start targeted for the first quarter of 2027.
Palisade Bio said its cash resources are expected to fund operations through key Phase 2 clinical readouts in 2027 and 2028.
